Profile
International Journal of Clinical Research & Trials Volume 5 (2020), Article ID 5:IJCRT-150, 3 pages
https://doi.org/10.15344/2456-8007/2020/150
Case Report
Valproic Acid Induced Pleural Effusion: A Rare Clinical and Pathophysiological Entity

Efthymia Papadopoulou1, Stavros Tryfon1,*, Maria Saroglou2, Dimitrios Vlachopoulos2, Athina Georgopoulou1 and Eva Serasli1

1Pulmonary Department of NHS, General Hospital “George Papanikolaou”, Thessaloniki, Greece
2Private Medicine, Thessaloniki, Greece
Dr. Stavros M. Tryfon, General Hospital “George Papanikolaou”, Thessaloniki, Greece, Tel: +30.6944597560, Fax: +30 2313 307286; E-mail: stavrostryfon@yahoo.gr
17 July 2020; 20 August 2020; 22 August 2020
Papadopoulou E, Tryfon S, Saroglou M, Vlachopoulos D, Georgopoulou A, et al. (2020) Valproic Acid Induced Pleural Effusion: A Rare Clinical and Pathophysiological Entity Int J Clin Res Trials 5: 150. doi: https://doi.org/10.15344/2456-8007/2020/150

Abstract

Introduction: Among the reported cases of valproic acid - induced pleural effusion, recurrence of pleural fluid accumulation has scarcely been presented in the literature.
Case presentation: This case study reports a 51-year-old man under treatment with valproic acid, who presented with recurrent pleural effusion characterized by transition from eosinophilic to lymphocytic predominance. The recurrence of the effusion upon re-administration of the drug, along with its resolution upon discontinuation of treatment with valproic acid, is strongly indicative of a causative association.
Conclusion: This is the first reported case of recurrent valproic acid - induced pleural effusion presenting with transition from eosinophilic to lymphocytic predominance. We aim to highlight the importance of taking into consideration the causative role of valproic acid in inducing pleural effusion, even when the pleural fluid demonstrates alteration in the predominant cell type.